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WHO’s Global Action Plan for tackling non-communicable 
diseases (NCDs) aims for 80% availability and aﬀ ordability 
of essential medicines for NCDs in both public and 
private facilities,1 but in low-income and middle-income 
countries these medicines remain both poorly available 
(particularly in the public sector) and inordinately 
expensive.2,3 Access to medicines plays a vital part in 
achieving universal health-care coverage and many of 
the barriers to expanding universal health-care coverage 
relate to how medicines are purchased and used.4
The challenges of access to essential medicines for 
NCDs fall into four distinct categories: generic oral 
medicines available cheaply on the international market 
but intermittently available in countries and of uneven 
quality; asthma inhalers and insulin available at high cost, 
and quality assessment being highly challenging; NCD 
medicines still under patent and accessible only through 
expanded access programmes; and opioid analgesics for 
palliative care often limited by excessive regulation.
Global initiatives have shown that it is possible to 
deliver care and medicines for a complex chronic disease 
in low-income and middle-income countries.5 The 
Global Fund to Fight AIDS, TB and Malaria (GFATM) and 
the Clinton Foundation HIV/AIDS Initiative use pooled 
procurement and negotiate prices with suppliers. 
Issues about quality of medicines have been addressed 
through the WHO prequaliﬁ cation scheme that assesses 
both the product dossier and related manufacturing 
site, which helps UN agencies, the GFATM, and countries 
purchase medicines of guaranteed quality, safety, and 
eﬀ ectiveness.6 Like other initiatives, such as UNITAID 
and GAVI, these disease-oriented supply mechanisms 
have been well funded. By contrast, initiatives for NCDs 
have relied on donations or restricted tiered pricing and 
have been limited in terms of scope and sustainability.
Two NCD schemes might provide pointers for future 
directions. The Global Task Force on Expanded Access to 
Cancer Care and Control helps with delivery of aﬀ ordable 
cancer drugs, vaccines, and services through assistance 
with ﬁ nance and procurement.7 The Asthma Drug 
Facility8 established and run by International Union 
Against Tuberculosis and Lung Disease has assisted 
low-income and middle-income countries to reduce by 
half the cost of quality-assured asthma inhalers through 
a quality assurance system based on WHO standards and 
a transparent tendering process.
Combining these initiatives as a basis for an NCD 
Drug Facility might oﬀ er an attractive route to 
improve the international availability and aﬀ ordability 
of quality generic medicines for NCDs. This Facility 
would need to assist countries in tackling other 
barriers, such as selection, tendering, purchasing, 
distribution, prescription, and use, through health 
system strengthening. There are also potential dangers 
of creating parallel, vertical programmes that require 
substantial international ﬁ nancial support.
Creating an NCD Drug Information Facility may address 
many of the barriers that exist with fewer challenges 
and lower costs by obtaining information on diﬀ erent 
medicines, their suppliers, prices, and quality, with 
the dossier of each manufacturer being assessed by 
independent and qualiﬁ ed experts. Countries would 
be able to access the information to enable them to 
obtain medicines from the best source. Provision of this 
information might also foster competition, as diﬀ erent 
suppliers would be able to see the overall market for their 
competitor’s products. The NCD Drug Information Facility 
would help develop and implement proper training and 
evidence-based guidelines for people in the medicine 
supply chain, pharmacists and clinicians, and support 
countries in doing monitoring surveys to measure and 
report the availability, price, aﬀ ordability, and use of 
essential NCD medicines with established methods.9,10
Given the nature of the NCD Drug Information 
Facility’s proposed role and the need for independence, 
its natural home would be within WHO. The expertise is 
also present at WHO, with regional oﬃ  ces, for example 
PAHO, being able to pilot such an initiative in-country. 
The aim of the NCD Drug Information Facility would 
be to support WHO in providing a channel for all 
Member States to attain the globally agreed target of 
80% availability and aﬀ ordability of generic essential 
medicines for major NCDs. This target from the Global 
Action Plan is the only one related to health systems 
and should serve as an opportunity for WHO, Member 
States, and other partners active in NCDs. A WHO-led 
Improving global access to medicines for non-communicable 
diseases
Comment
e562 www.thelancet.com/lancetgh   Vol 2   October 2014
multistakeholder meeting backed by a resolution at 
the World Health Assembly would be the natural next 
steps to move forwards with a health system approach 
to NCDs to contribute to reducing premature mortality1 
and the wider aim of universal health-care coverage.
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